Replies to post #5272 on Titan Pharmaceuticals Inc (TTNP)

[TRUISM]

There's Probuphine to consider,with potential European talks later this year (after Probuphine clinical trial results are released).

Additionally,one must consider the Drug Delivery technology

Continuous Drug Delivery Technology
The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.

And any considerations going forward, such as Parkinsons (possibly pain,etc., etc.)


This could mark a "new day" for TTNP....


With positive clinical trial results for Probuphine going forward and falling in line with the FDA's parameters,things could get quite interesting around here....


And rather quickly.




Blessings to All

TRUTH